Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia

Giorgio Lambertenghi-Deliliers, Anna Teresa Maiolo, Claudio Annaloro, Agostino Cortelezzi, Enrico Pogliani, Fabrizio Ganzina, Elio E. Polli

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Sixteen adult patients with refractory acute non-lymphoblastic leukemia (ANLL) underwent reinduction therapy with idarubicin (12 mg/m2) i.v. on days 1-3) followed by cytosine arabinoside (120 mg/m2 every 120 h on days 4-10). Patients achieving complete remission (CR) received consolidation and early intensification courses which included idarubicin at lower dosage. CR was reached after a single course in 70% of the patients treated at first relapse, and two of the five subjects previously resistant to daunorubicin-containing regimens responsed to the idarubicin protocol. The median duration of CR was 11 months. Gastrointestinal side-effects were not important; mild and reversible ECG changes were noted whereas delayed cardiac toxicity was not observed despite previous treatment with daunorubicin. These encouraging results confirm the efficay of idarubicin in treating acute leukemia and suggest it may have a major role in the treatment of relapsed and refractory patients with ANLL.

Original languageEnglish
Pages (from-to)1041-1045
Number of pages5
JournalEuropean Journal of Cancer and Clinical Oncology
Volume23
Issue number7
DOIs
Publication statusPublished - 1987

Fingerprint

Idarubicin
Cytarabine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Daunorubicin
Therapeutics
Electrocardiography
Leukemia
Recurrence

ASJC Scopus subject areas

  • Oncology

Cite this

Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia. / Lambertenghi-Deliliers, Giorgio; Maiolo, Anna Teresa; Annaloro, Claudio; Cortelezzi, Agostino; Pogliani, Enrico; Ganzina, Fabrizio; Polli, Elio E.

In: European Journal of Cancer and Clinical Oncology, Vol. 23, No. 7, 1987, p. 1041-1045.

Research output: Contribution to journalArticle

Lambertenghi-Deliliers, Giorgio ; Maiolo, Anna Teresa ; Annaloro, Claudio ; Cortelezzi, Agostino ; Pogliani, Enrico ; Ganzina, Fabrizio ; Polli, Elio E. / Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia. In: European Journal of Cancer and Clinical Oncology. 1987 ; Vol. 23, No. 7. pp. 1041-1045.
@article{c4143c4f99a849449aa916f93769bd47,
title = "Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia",
abstract = "Sixteen adult patients with refractory acute non-lymphoblastic leukemia (ANLL) underwent reinduction therapy with idarubicin (12 mg/m2) i.v. on days 1-3) followed by cytosine arabinoside (120 mg/m2 every 120 h on days 4-10). Patients achieving complete remission (CR) received consolidation and early intensification courses which included idarubicin at lower dosage. CR was reached after a single course in 70{\%} of the patients treated at first relapse, and two of the five subjects previously resistant to daunorubicin-containing regimens responsed to the idarubicin protocol. The median duration of CR was 11 months. Gastrointestinal side-effects were not important; mild and reversible ECG changes were noted whereas delayed cardiac toxicity was not observed despite previous treatment with daunorubicin. These encouraging results confirm the efficay of idarubicin in treating acute leukemia and suggest it may have a major role in the treatment of relapsed and refractory patients with ANLL.",
author = "Giorgio Lambertenghi-Deliliers and Maiolo, {Anna Teresa} and Claudio Annaloro and Agostino Cortelezzi and Enrico Pogliani and Fabrizio Ganzina and Polli, {Elio E.}",
year = "1987",
doi = "10.1016/0277-5379(87)90356-7",
language = "English",
volume = "23",
pages = "1041--1045",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "7",

}

TY - JOUR

T1 - Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia

AU - Lambertenghi-Deliliers, Giorgio

AU - Maiolo, Anna Teresa

AU - Annaloro, Claudio

AU - Cortelezzi, Agostino

AU - Pogliani, Enrico

AU - Ganzina, Fabrizio

AU - Polli, Elio E.

PY - 1987

Y1 - 1987

N2 - Sixteen adult patients with refractory acute non-lymphoblastic leukemia (ANLL) underwent reinduction therapy with idarubicin (12 mg/m2) i.v. on days 1-3) followed by cytosine arabinoside (120 mg/m2 every 120 h on days 4-10). Patients achieving complete remission (CR) received consolidation and early intensification courses which included idarubicin at lower dosage. CR was reached after a single course in 70% of the patients treated at first relapse, and two of the five subjects previously resistant to daunorubicin-containing regimens responsed to the idarubicin protocol. The median duration of CR was 11 months. Gastrointestinal side-effects were not important; mild and reversible ECG changes were noted whereas delayed cardiac toxicity was not observed despite previous treatment with daunorubicin. These encouraging results confirm the efficay of idarubicin in treating acute leukemia and suggest it may have a major role in the treatment of relapsed and refractory patients with ANLL.

AB - Sixteen adult patients with refractory acute non-lymphoblastic leukemia (ANLL) underwent reinduction therapy with idarubicin (12 mg/m2) i.v. on days 1-3) followed by cytosine arabinoside (120 mg/m2 every 120 h on days 4-10). Patients achieving complete remission (CR) received consolidation and early intensification courses which included idarubicin at lower dosage. CR was reached after a single course in 70% of the patients treated at first relapse, and two of the five subjects previously resistant to daunorubicin-containing regimens responsed to the idarubicin protocol. The median duration of CR was 11 months. Gastrointestinal side-effects were not important; mild and reversible ECG changes were noted whereas delayed cardiac toxicity was not observed despite previous treatment with daunorubicin. These encouraging results confirm the efficay of idarubicin in treating acute leukemia and suggest it may have a major role in the treatment of relapsed and refractory patients with ANLL.

UR - http://www.scopus.com/inward/record.url?scp=0023264088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023264088&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(87)90356-7

DO - 10.1016/0277-5379(87)90356-7

M3 - Article

C2 - 3478198

AN - SCOPUS:0023264088

VL - 23

SP - 1041

EP - 1045

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 7

ER -